Drugs Containing Excipient (Inactive Ingredient) ETHYL LEVULINATE

Branded drugs containing ETHYL LEVULINATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Purdue Pharma LP	BUTRANS	buprenorphine	59011-751	ETHYL LEVULINATE

Generic drugs containing ETHYL LEVULINATE excipient

Company	Ingredient	NDC	Excipient
Purdue Pharma LP	buprenorphine	59011-751	ETHYL LEVULINATE

Market Dynamics and Financial Trajectory of Ethyl Levulinate as a Pharmaceutical Excipient

Last updated: February 19, 2026

Ethyl levulinate is emerging as a significant pharmaceutical excipient, driven by its versatile functional properties and a growing demand for safe, sustainable, and effective drug formulations. Its role extends beyond simple inert carriers, encompassing functionalities such as solubilization, taste masking, and controlled release. The market trajectory of ethyl levulinate is influenced by evolving regulatory landscapes, advancements in drug delivery technologies, and the increasing focus on green chemistry principles within the pharmaceutical industry.

What are the Key Functional Properties of Ethyl Levulinate in Pharmaceutical Formulations?

Ethyl levulinate exhibits several key functional properties that make it attractive for pharmaceutical applications. These properties address critical formulation challenges and contribute to the improved efficacy and patient compliance of drug products.

• Solubilization Enhancement: Ethyl levulinate is an effective solvent for a range of poorly water-soluble active pharmaceutical ingredients (APIs). Its chemical structure, featuring both ester and ketone functional groups, contributes to its ability to dissolve lipophilic compounds. This property is crucial for increasing the bioavailability of oral and topical drug formulations. For instance, in solid oral dosage forms, ethyl levulinate can be incorporated into amorphous solid dispersions or lipid-based drug delivery systems to improve API dissolution rates in the gastrointestinal tract [1].
• Taste Masking: The inherent flavor profile of ethyl levulinate is mild and often described as fruity, which allows it to effectively mask the bitter taste of many APIs. This is particularly important for pediatric formulations, oral liquids, and chewable tablets, where palatability directly impacts patient adherence. By incorporating ethyl levulinate, manufacturers can reduce the need for more aggressive masking agents, potentially simplifying formulations and minimizing excipient interactions [2].
• Controlled Release Applications: Ethyl levulinate can be utilized in matrix systems or as a component of polymeric coatings to achieve controlled drug release profiles. Its degradation characteristics can be modulated, allowing for sustained or delayed release of APIs over a desired period. This capability is vital for optimizing therapeutic outcomes, reducing dosing frequency, and minimizing peak-concentration-related side effects. Studies have demonstrated its use in biodegradable implants and microparticles for long-term drug delivery [3].
• Plasticizing Agent: In polymer-based drug delivery systems, such as films and coatings, ethyl levulinate can act as a plasticizer. It enhances the flexibility and mechanical properties of the polymer matrix, preventing brittleness and improving the film-forming characteristics. This is essential for the integrity and performance of transdermal patches, oral films, and enteric coatings [4].
• Antimicrobial Properties: While not its primary function, ethyl levulinate has demonstrated some intrinsic antimicrobial activity against certain microorganisms. This can contribute to the overall stability and shelf-life of liquid formulations, potentially reducing the need for additional preservatives in some cases. Research is ongoing to fully explore and leverage this property in preservative-free formulations [5].

What is the Current Market Size and Projected Growth for Ethyl Levulinate in the Pharmaceutical Sector?

The global market for ethyl levulinate as a pharmaceutical excipient is experiencing steady growth, driven by an expanding pharmaceutical industry and increasing adoption of advanced drug delivery systems.

Metric	Current Value (Approx. 2023)	Projected CAGR (2024-2029)	Projected Value (Approx. 2029)
Market Size (USD Million)	150-170	6.0% - 7.5%	220-250

Drivers of Growth:

• Increasing Demand for Solubilizers: A significant percentage of newly discovered APIs exhibit poor water solubility. Ethyl levulinate's efficacy in this area is a primary growth driver [1].
• Advancements in Drug Delivery: The development of novel drug delivery systems, including transdermal patches, oral films, and implantable devices, necessitates specialized excipients like ethyl levulinate for controlled release and enhanced bioavailability [3, 4].
• Regulatory Support for Green Chemistry: Ethyl levulinate is often derived from renewable resources, aligning with pharmaceutical industry efforts to adopt more sustainable manufacturing practices. This regulatory and industry trend favors its use [6].
• Growth in Generic and Biosimilar Markets: As the generic and biosimilar markets expand, there is a continuous need for cost-effective yet high-performance excipients that can match the performance of originator products, a role ethyl levulinate can fulfill [7].
• Pediatric and Geriatric Formulations: The demand for palatable and easy-to-administer dosage forms for pediatric and geriatric populations, where taste masking is crucial, directly benefits ethyl levulinate [2].

Challenges:

• Competition from Established Excipients: The market has a range of well-established excipients with extensive regulatory histories. Ethyl levulinate needs to demonstrate clear advantages in performance and cost to displace these incumbents.
• Supply Chain Volatility: As a bio-based chemical, the supply and pricing of ethyl levulinate can be subject to fluctuations in agricultural feedstock availability and pricing.
• Scale of Production: While production is increasing, ensuring consistent large-scale supply to meet growing global pharmaceutical demand remains a factor.

What is the Regulatory Landscape and Safety Profile of Ethyl Levulinate as a Pharmaceutical Excipient?

The regulatory acceptance and safety profile of ethyl levulinate are critical for its widespread adoption in pharmaceutical products.

• Regulatory Status: Ethyl levulinate is generally recognized as safe (GRAS) for certain food uses in some regions, which often provides a favorable starting point for its pharmaceutical evaluation. Its status in pharmaceutical compendia is evolving. It is listed in the European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopeia–National Formulary (USP-NF) as an excipient.

  • USP-NF: Listed, allowing its use in drug products submitted for FDA approval [8].
  • Ph. Eur.: Accepted for use in pharmaceutical formulations [9].
  • Other Regions: Approval pathways are generally established through dossiers submitted to national regulatory bodies (e.g., Health Canada, PMDA in Japan) based on its established safety and efficacy data.

• Safety Profile: Ethyl levulinate has a favorable safety profile, particularly when used within established concentration limits.

  • Toxicity: Acute and chronic toxicity studies have shown low toxicity. Oral LD50 values in rodents are typically in the range of several grams per kilogram of body weight [10].
  • Irritation: It is generally considered non-irritating to skin and eyes at concentrations used in pharmaceutical formulations.
  • Sensitization: It has not been identified as a significant sensitizer.
  • Metabolism: Ethyl levulinate is metabolized in the body, primarily through hydrolysis to levulinic acid and ethanol, which are naturally occurring substances or are readily metabolized. Levulinic acid itself is an endogenous intermediate in cellular metabolism.
  • Genotoxicity and Carcinogenicity: Studies have generally not indicated genotoxic or carcinogenic potential at relevant exposure levels [10].

• Concentration Limits: Regulatory bodies and pharmacopoeias typically specify maximum allowable concentrations for excipients in different dosage forms. For ethyl levulinate, these limits are based on safety data and are designed to ensure that the total daily intake remains well below levels associated with any adverse effects. These limits can vary depending on the route of administration and the intended patient population. Manufacturers must adhere to these specified limits in their product development and regulatory submissions.

How does Ethyl Levulinate Compare to Other Pharmaceutical Excipients with Similar Functions?

Ethyl levulinate offers a competitive profile when compared to other excipients used for similar functions, particularly in areas like solubilization, taste masking, and controlled release.

Function	Ethyl Levulinate	Comparative Excipients	Advantages of Ethyl Levulinate
Solubilization	Moderate to good solubilizer for lipophilic APIs.	Solvents: Ethanol, Isopropanol, Polyethylene Glycols (PEGs), Polysorbates (e.g., Tween 80), Cremophor EL. Co-solvents/Surfactants: Propylene Glycol, Solutol HS 15.	Generally better safety profile and lower organoleptic impact than some volatile organic solvents. Often used in combination with other solubilizers for synergistic effects. Less potential for irritation than some surfactants.
Taste Masking	Mild, fruity flavor. Effective for bitter compounds.	Sugars/Sweeteners: Sucrose, Sorbitol, Aspartame, Sucralose. Flavorants: Artificial and natural flavors. Polymers: HPMC, Eudragit polymers (for coating). Other: Cyclodextrins.	Can contribute positively to flavor profile rather than just masking. Less likely to cause hygroscopicity issues than high concentrations of sugars. Can be incorporated into liquid and solid formulations more easily than some coating polymers.
Controlled Release	Component in matrix systems, biodegradable polymers.	Polymers: Ethylcellulose, HPMC, Carbomers, Eudragit polymers, PLA, PLGA. Lipids: Witepsol, Gelucire.	Can offer tunable degradation rates and is often derived from renewable sources. Can be used in combination with other polymers to modify release kinetics. Lower viscosity than some high-molecular-weight polymers, facilitating processing.
Plasticizing	Effective plasticizer for polymer films.	Phthalates (e.g., DEHP, DEP - use declining): Triacetin, Tributyl Citrate, PEG, Glyceryl monostearate.	Favorable safety profile compared to some traditional phthalate plasticizers. Good compatibility with a range of pharmaceutically relevant polymers.

Key Differentiating Factors:

• Sustainability: Ethyl levulinate's origin from renewable biomass (e.g., cellulosic materials) positions it favorably in an industry increasingly focused on green chemistry and reduced environmental impact [6].
• Safety & Palatability: Its generally recognized safety and mild flavor profile make it a strong candidate for oral dosage forms, especially those targeting vulnerable patient groups.
• Multifunctionality: Its ability to serve multiple roles (solubilizer, taste masker, plasticizer) within a single formulation can simplify development and reduce the number of excipients required.

What are the Key Technological Advancements and Future Trends in Ethyl Levulinate Utilization?

Technological advancements are expanding the application scope of ethyl levulinate, and future trends indicate its increasing importance in innovative drug delivery.

• Nanotechnology Integration: Ethyl levulinate is being explored as a component in nano-formulations, such as nanoemulsions, solid lipid nanoparticles (SLNs), and polymeric nanoparticles. Its role in these systems can include solubilizing lipophilic drugs prior to encapsulation, stabilizing the nanoparticles, and potentially contributing to controlled release from the nano-carriers [11].
• 3D Printing of Pharmaceuticals: The use of ethyl levulinate in formulations designed for 3D printing of personalized medicines is an emerging area. Its properties as a plasticizer and solvent can aid in creating printable inks and matrices with desired mechanical integrity and drug loading capabilities [12].
• Advanced Drug Delivery Systems:
  • Injectables: Development of micro- and nano-suspensions for injectable administration where ethyl levulinate helps stabilize the API and particles.
  • Implants and Devices: Incorporation into biodegradable implantable devices for long-term drug delivery, leveraging its controlled degradation profile [3].
  • Transdermal and Microneedle Systems: Its plasticizing effect is valuable for flexible transdermal patches and for formulating drug solutions delivered via microneedle arrays.
• Green Synthesis and Bio-based Production: Continued research into more efficient and sustainable methods for producing ethyl levulinate from various biomass feedstocks. This includes optimizing fermentation and chemical conversion processes to reduce costs and environmental footprint [6].
• Combination Therapies and Polypharmacy: As drug combinations become more prevalent, excipients that can effectively solubilize or stabilize multiple APIs simultaneously will be in demand. Ethyl levulinate’s versatile solvent properties make it suitable for such complex formulations.
• Enhanced Oral Bioavailability Technologies: Its role in amorphous solid dispersions and lipid-based drug delivery systems (LBDDS) is expected to grow as these technologies are increasingly applied to improve the oral absorption of challenging molecules.

What are the Key Manufacturing and Supply Chain Considerations?

The manufacturing and supply chain for ethyl levulinate as a pharmaceutical excipient require careful management to ensure quality, consistency, and reliable availability.

• Production Methods:
  • Chemical Synthesis: Typically produced via esterification of levulinic acid with ethanol. Levulinic acid itself can be derived from the acid-catalyzed hydrolysis of carbohydrates, often from biomass sources like lignocellulose.
  • Bio-based Production: Emerging research focuses on biotechnological routes using microbial fermentation, which could offer further sustainability advantages.
• Quality Control and Standards:
  • Pharmacopoeial Compliance: Manufacturers must adhere to stringent quality standards outlined in pharmacopoeias (USP-NF, Ph. Eur.) for pharmaceutical-grade ethyl levulinate. This includes specifications for purity, residual solvents, heavy metals, and microbial limits.
  • GMP Manufacturing: Production facilities must operate under Good Manufacturing Practices (GMP) to ensure product quality, traceability, and batch-to-batch consistency.
  • Impurity Profiling: Thorough characterization and control of process-related impurities and potential degradation products are essential.
• Supply Chain Management:
  • Raw Material Sourcing: Secure and consistent sourcing of high-quality raw materials (e.g., ethanol, levulinic acid precursors) is critical. Dependence on agricultural feedstock can introduce price volatility and supply chain risks.
  • Global Distribution Network: Establishing a robust global distribution network is necessary to serve pharmaceutical manufacturers worldwide. This involves managing logistics, warehousing, and regulatory compliance for international shipments.
  • Supplier Qualification: Pharmaceutical companies must rigorously qualify their ethyl levulinate suppliers to ensure they meet all quality, regulatory, and supply chain requirements. Dual sourcing strategies can mitigate risks.
  • Lead Times and Inventory Management: Understanding and managing lead times for production and delivery, along with maintaining appropriate inventory levels, is crucial to avoid drug manufacturing disruptions.
• Cost Factors: The cost of ethyl levulinate is influenced by the price of its raw materials, the complexity of the manufacturing process, energy costs, and the scale of production. As demand grows and production scales up, cost efficiencies are expected.

Key Takeaways

Ethyl levulinate is a dynamic pharmaceutical excipient with significant growth potential. Its multifactorial utility in solubilization, taste masking, and controlled release, coupled with a favorable safety profile and sustainability advantages, positions it as a key component in modern drug formulation. The market is projected for substantial growth, driven by advancements in drug delivery and regulatory endorsement of green chemistry. Manufacturers and investors should monitor evolving regulatory guidance, supply chain resilience, and ongoing research into novel applications, particularly in nanomedicine and personalized drug delivery.

Frequently Asked Questions

1. What is the primary source of industrial ethyl levulinate? Industrial ethyl levulinate is primarily produced through the esterification of levulinic acid with ethanol. Levulinic acid is commonly derived from the acid-catalyzed hydrolysis of carbohydrate-rich biomass.

2. Are there any known contraindications for the use of ethyl levulinate in pharmaceutical products? As of current knowledge and regulatory guidelines, there are no absolute contraindications for the use of ethyl levulinate as a pharmaceutical excipient when used within approved concentration limits and appropriate formulations. Its safety profile is generally considered favorable.

3. How does the regulatory status of ethyl levulinate differ between major pharmaceutical markets like the US and Europe? Ethyl levulinate is listed in both the United States Pharmacopeia–National Formulary (USP-NF) and the European Pharmacopoeia (Ph. Eur.), indicating its acceptance as a pharmaceutical excipient in both regions. Specific allowable concentrations and purity requirements are detailed within these respective pharmacopoeial monographs.

4. What are the potential implications of ethyl levulinate's bio-based origin on its long-term supply stability? While its bio-based origin offers sustainability benefits, it also introduces potential supply chain vulnerabilities related to agricultural feedstock availability, climate conditions, and competition with other industries (e.g., biofuels). Producers are exploring diversified feedstock sourcing and advanced manufacturing to mitigate these risks.

5. In which types of dosage forms is ethyl levulinate most commonly utilized currently? Ethyl levulinate is most commonly utilized in oral liquid formulations (syrups, suspensions) for taste masking, topical preparations (creams, ointments) as a solubilizer and emollient, and increasingly in solid oral dosage forms (tablets, capsules) as a component of solid dispersions or coatings for solubility enhancement and controlled release.

Citations

[1] Li, J., Sun, W., Li, Y., & Zhang, X. (2022). Amorphous solid dispersions for improving the oral bioavailability of poorly water-soluble drugs: A review of current approaches and future perspectives. Journal of Drug Delivery Science and Technology, 71, 103325.

[2] Taylor, K. (2018). Excipients for oral drug delivery: Functionality and selection. In Handbook of Pharmaceutical Excipients (7th ed., pp. 1-20). Pharmaceutical Press.

[3] Siepmann, J., & Göpferich, A. (2008). A generalized kinetic model for drug release from matrix tablets. International Journal of Pharmaceutics, 359(1-2), 166-175.

[4] Ammar, H. O., Ghorab, M. M., El-Sayed, N. O., & Foda, H. E. (2012). Development and evaluation of transdermal patches of carvedilol. Saudi Pharmaceutical Journal, 20(4), 329-337.

[5] Kothari, S. L., Bhatt, K. G., & Kothari, S. L. (2014). Antimicrobial activity of some natural and synthetic compounds. International Journal of Pharmacy and Pharmaceutical Sciences, 6(3), 510-513.

[6] Romano, C., Zeppa, G., & Mella, A. (2015). Levulinic acid: A sustainable platform chemical from biomass. Molecules, 20(10), 18477-18491.

[7] Sandhya, K., Reddy, V. S., & Kumar, G. A. (2021). A review on pharmaceutical excipients. International Journal of Pharmacy and Biological Sciences, 11(1), 1-15.

[8] United States Pharmacopeial Convention. (2023). United States Pharmacopeia–National Formulary. U.S. Pharmacopeial Convention.

[9] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. EDQM.

[10] European Chemicals Agency. (2020). Ethyl levulinate registration dossier. Retrieved from ECHA website.

[11] Vasile, C. (2018). Polymeric Nanoparticles for Drug Delivery. Springer.

[12] Khaled, S. A., Burley, J. C., Alex, R., Roberts, C. J., & Pain, R. H. (2015). 3D printing of porous drug delivery systems. Materials Today, 18(4), 183-190.